Udvalget har fundet, at fordelene ved Baraclude opvejer risiciene til behandling af patienter med kronisk hepatitis B med kompenseret leversygdom.
They decided that Baraclude’ s benefits are greater than its risks for the treatment of patients with chronic hepatitis B with compensated liver disease.